Publication: Efectividad y seguridad a largo plazo de los antivirales de acción directa en pacientes con hepatitis C crónica de un hospital terciario
Loading...
Files
Official URL
Full text at PDC
Publication Date
2019-12-19
Authors
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Universidad Complutense de Madrid
Citations
Exportar
Abstract
La hepatitis crónica por virus hepatitis C (VHC) constituye un problema de salud de primer nivel, con 71 millones de personas afectadas, responsable de una importante morbimortalidad hepática y extrahepática. La infección por el VHC puede progresar a enfermedad hepática avanzada, cirrosis y carcinoma hepatocelular (CHC).El tratamiento para la infección por VHC ha cambiado radicalmente en los últimos años debido a la aparición de fármacos antivirales de acción directa (AAD) de segunda generación que se combinan entre sí y actúan sobre diferentes dianas terapéuticas claves para la replicación del virus, consiguiéndose tasas de respuesta viral sostenida (RVS) superiores al 95% en la mayor parte de los pacientes. Son regímenes de tratamiento de corta duración, administrados por vía oral y con escasos efectos adversos asociados, lo que se traduce en mayor comodidad y adherencia al tratamiento por parte de los pacientes.Después del tratamiento con AAD se espera la erradicación del virus y la mejora de la función hepática, grado de fibrosis y disminución de riesgo de desarrollo de CHC y otros tumores extrahepáticos..
Hepatitis C is a major health problem, with 71 million people affected worlwide, responsible for significant hepatic and extrahepatic morbidity and mortality. The infection by hepatitis C virus can progress to advanced liver disease, cirrosis and hepatcellular carcinoma.The treatment of hepatitis C virus infection has changed radically in recent years due the emergence of direct-acting antivirals that combine with each other and act on different therapeutic targets key for virus replication, achieving sustained virologic response rates higher than 95% in most patients. These are short duration treatment regimens, administered orally, with little adverse effects associated, which results in greater comfort and adherence. After the treatment with direct-acting antivirals, the HCV eradication, improvement of liver function, improvement in the degree of hepatic fibrosis, risk reduction for developing hepatocellular carcinoma and other extrahepatic tumors are expected..
Hepatitis C is a major health problem, with 71 million people affected worlwide, responsible for significant hepatic and extrahepatic morbidity and mortality. The infection by hepatitis C virus can progress to advanced liver disease, cirrosis and hepatcellular carcinoma.The treatment of hepatitis C virus infection has changed radically in recent years due the emergence of direct-acting antivirals that combine with each other and act on different therapeutic targets key for virus replication, achieving sustained virologic response rates higher than 95% in most patients. These are short duration treatment regimens, administered orally, with little adverse effects associated, which results in greater comfort and adherence. After the treatment with direct-acting antivirals, the HCV eradication, improvement of liver function, improvement in the degree of hepatic fibrosis, risk reduction for developing hepatocellular carcinoma and other extrahepatic tumors are expected..
Description
Tesis inédita de la Universidad Complutense de Madrid, Facultad de Farmacia, leída el 14-11-2019